Cantargia AB (FRA:7V3)
€ 0.305 -0.002 (-0.65%) Market Cap: 50.72 Mil Enterprise Value: 41.52 Mil PE Ratio: 0 PB Ratio: 7.71 GF Score: 40/100

Q1 2022 Cantargia AB Earnings Call Transcript

May 23, 2022 / 08:00AM GMT
Release Date Price: €1.11 (-1.54%)
GÃ;ran Forsberg
Cantargia AB - CEO

¶ -

Thank you so much. It's a pleasure to present our Q1 report. And if we move to slide 2 and then to slide 3, I can say that it's me, Forsberg and the CFO of Cantargia, Bengt Jöndell, who would do his presentation.

And then the going to slide number 4. We've been running through in a way and at a period with lots of news flow, but lots of news flow had the one chance of the lead project, that's been around stocking up new trials, so first patient in and things like that. So that's a very important event because it means that new activities are starting.

But from the results point of view, we have had much more, let's say, progress in the second project, the CAN10 program where we present new results in systemic sclerosis during the period. And also yesterday, we could present some very exciting results in atherosclerosis, which is not the lead indication, but still very exciting and really a new opportunity for our program.

And another important event also, which happened already early January, it's that we signed an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot